Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preoperative Treatment With mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose Stereotactic Body Radiation Therapy (iHD-SBRT) for Borderline Resectable Pancreatic Adenocarcinoma: a Randomised Phase II Study (STEREOPAC)

NCT05083247 is registered in ClinicalTrials.gov with Erasme University Hospital as lead sponsor.

NCT NCT05083247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05083247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preoperative Treatment With mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose Stereotactic Body Radiation Therapy (iHD-SBRT) for Borderline Resectable Pancreatic Adenocarcinoma: a Randomised Phase II Study (STEREOPAC)
Lead sponsor
Erasme University Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
March 24, 2023
Completion date
December 31, 2030
Enrollment
256 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

borderline resectable pancreatic adenocarcinoma, pancreatic adenocarcinoma, pancreatic neoplasm